Skip to main content

Merck & Co., Inc 10-Q for FY2026 Q3

Merck & Co., Inc. (MRK)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Merck & Co., Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Merck recorded a $9.0 billion R&D charge after acquiring Cidara Therapeutics, Inc. for $9.2 billion in May 2026. Worldwide sales increased 5% to $18.1 billion in the third quarter of 2026 amid pricing pressure. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$18.09B
up 4.7% from $17.28B a year earlier
Net income
$5.07B
down 12.4% from net income of $5.79B a year earlier
Diluted EPS
$2.04
down 12.1% from $2.32 a year earlier